Colchicine prophylaxis is associated with fewer gout flares after COVID-19 vaccination.
Ann Rheum Dis
; 81(8): 1189-1193, 2022 08.
Artículo
en Inglés
| MEDLINE | ID: covidwho-1741595
ABSTRACT
OBJECTIVES:
COVID-19 vaccination often triggers a constellation of transitory inflammatory symptoms. Gout is associated with several comorbidities linked to poor outcomes in COVID-19, and gout flares can be triggered by some vaccinations. We analysed the risk of gout flares in the first 3 months after COVID-19 vaccination with inactivated virus, and whether colchicine can prevent gout flares following post-COVID-19 vaccination.METHODS:
A clinical delivery population-based cross-sectional study was conducted in the Gout Clinic at the Affiliated Hospital of Qingdao University between February and October 2021. Study participants were selected using a systematic random sampling technique among follow-up patients with gout. We collected data, including vaccinations and potential risk factors, using a combination of interviews, health QR codes and medical records. Logistic regression was used to adjust for covariates.RESULTS:
We enrolled 549 gout participants (median age 39 years, 84.2% vaccinated). For the 462 patients who received COVID-19 vaccine, 203 (43.9%) developed at least one gout flare in the 3 months after vaccination. Most of these flares were experienced within 1 month after the first (99/119 (83.2%)) or second (70/115 (60.9%)) dose of vaccine. Compared with unvaccinated participants, COVID-19 vaccination was associated with higher odds of gout flare within 3 months (adjusted OR 6.02; 95% CI 3.00 to 12.08). Colchicine use was associated with 47% less likelihood of postvaccine gout flare.CONCLUSION:
COVID-19 vaccination was associated with increased odds of gout flare, which developed mainly in month 1 after each vaccine dose, and was negatively associated with colchicine prophylaxis.Palabras clave
Texto completo:
Disponible
Colección:
Bases de datos internacionales
Base de datos:
MEDLINE
Asunto principal:
Colchicina
/
Supresores de la Gota
/
Brote de los Síntomas
/
Vacunas contra la COVID-19
/
COVID-19
/
Gota
Tipo de estudio:
Estudio de cohorte
/
Estudio observacional
/
Estudio pronóstico
/
Ensayo controlado aleatorizado
/
Revisión sistemática/Meta análisis
Tópicos:
Covid persistente
/
Vacunas
Límite:
Adulto
/
Humanos
Idioma:
Inglés
Revista:
Ann Rheum Dis
Año:
2022
Tipo del documento:
Artículo
País de afiliación:
Annrheumdis-2022-222199
Similares
MEDLINE
...
LILACS
LIS